The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $0.51 for the day, down -6.53% from the previous closing price of $0.55. In other words, the price has decreased by -$6.53 from its previous closing price. On the day, 22.42 million shares were traded. DNA stock price reached its highest trading level at $0.5349 during the session, while it also had its lowest trading level at $0.5085.
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’24 when Dmytruk Mark E. sold 48,866 shares for $0.55 per share. The transaction valued at 26,827 led to the insider holds 984,662 shares of the business.
Coen Steven P. sold 13,440 shares of DNA for $7,379 on Jun 03 ’24. The insider now owns 178,832 shares after completing the transaction at $0.55 per share. On May 16 ’24, another insider, DEKKERS MARIJN E, who serves as the Director of the company, sold 265,000 shares for $0.83 each. As a result, the insider received 220,030 and left with 5,515,364 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 1136819072 and an Enterprise Value of 530875008. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.15 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 2.544 whereas that against EBITDA is -0.842.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is -40.21%, while the 200-Day Moving Average is calculated to be -61.96%.
Shares Statistics:
DNA traded an average of 40.54M shares per day over the past three months and 45358120 shares per day over the past ten days. A total of 1.53B shares are outstanding, with a floating share count of 1.39B. Insiders hold about 33.42% of the company’s shares, while institutions hold 58.26% stake in the company. Shares short for DNA as of 1715731200 were 274438764 with a Short Ratio of 6.77, compared to 1713139200 on 266527056. Therefore, it implies a Short% of Shares Outstanding of 274438764 and a Short% of Float of 22.27.
